Propranolol Hydrochloride Combined With Adebrelimab and Platinum-Based Chemotherapy in Small Cell Lung Cancer

This is a prospective multicenter, open-label, Phase I clinical study designed to evaluate the safety, tolerability, and preliminary efficacy of propranolol hydrochloride in combination with adebrelimab and platinum-based chemotherapy in patients with small cell lung cancer (SCLC).The study includes two cohorts: patients with previously untreated extensive-stage SCLC and patients with resectable early-stage (T1-2N0M0) SCLC. Propranolol hydrochloride is a beta- adrenergic blocking agent which is associated with augment of immune cell responses. Propranolol hydrochloride may improve the responses of immune checkpoint inhibitors in treating patients with SCLC.